CD274 and cancer: One strategy to counter PD-1 inhibition is by the systemic administration of anti-PD1 or anti-PD-L1 blocking antibodies, which has already been approved by the FDA for treating different cancers, although patients suffer the risk of developing autoimmune disorders12,13.